Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro

Detalhes bibliográficos
Autor(a) principal: Borges, Maihara da Silva
Data de Publicação: 2021
Outros Autores: Salles, Marcela Miranda, Camuzi, Ranieri Carvalho
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/23009
Resumo: Most antineoplastic agents can cause infusion reactions, the incidence and profile of which vary according to the characteristics of each drug, which may or may not be immune-mediated. In order to describe the profile of immediate adverse reactions to chemotherapy infusion in outpatients, we developed this exploratory, descriptive, cross-sectional and retrospective study, based on records of adverse reaction notifications carried out by the multidisciplinary team from March/2018 to March/2019, and the medical records of the participants. Adverse reactions immediate to chemotherapy infusion were ranked for severity according to the Common Terminology Criteria for Adverse Events and for causality using Naranjo's algorithm. Of a total of 6,832 intravenous chemotherapy facilities performed during the study period, 30 immediate adverse reactions were recorded, involving 28 patients (83% women), mainly with Paclitaxel (44%) and Carboplatin (20%). According to Naranjo, 60% of infusion reactions were classified as probable. The mean time for onset of reactions was 40 minutes, being the fastest with Docetaxel (5 minutes) and the longest with Paclitaxel (180 minutes). The severity of reactions ranged from mild (64%) to moderate (30%). The most compromised organic segments were respiratory (27%) and cardiovascular (26%); and 83% of the symptoms presented were predicted in the databases. With this study, it was possible to identify the main immediate reactions to the infusion in the study group, as well as the chemotherapeutic agents involved with them, contributing to the safe management of patients and effective control of reactions by the multidisciplinary team.
id UNIFEI_13b57a038a457a0dac6b8d3e75b4674c
oai_identifier_str oai:ojs.pkp.sfu.ca:article/23009
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de JaneiroPerfil de reacciones adversas inmediatas a la infusión de quimioterapia en pacientes ambulatorios de un Hospital Universitario de Río de JaneiroPerfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais em um Hospital Universitário fluminense QuimioterapiaEventos adversosFarmacovigilânciaSegurança do paciente.QuimioterapiaEventos adversosFarmacovigilanciaSeguridad del paciente.ChemotherapyAdverse eventsPharmacovigilancePatient safety.Most antineoplastic agents can cause infusion reactions, the incidence and profile of which vary according to the characteristics of each drug, which may or may not be immune-mediated. In order to describe the profile of immediate adverse reactions to chemotherapy infusion in outpatients, we developed this exploratory, descriptive, cross-sectional and retrospective study, based on records of adverse reaction notifications carried out by the multidisciplinary team from March/2018 to March/2019, and the medical records of the participants. Adverse reactions immediate to chemotherapy infusion were ranked for severity according to the Common Terminology Criteria for Adverse Events and for causality using Naranjo's algorithm. Of a total of 6,832 intravenous chemotherapy facilities performed during the study period, 30 immediate adverse reactions were recorded, involving 28 patients (83% women), mainly with Paclitaxel (44%) and Carboplatin (20%). According to Naranjo, 60% of infusion reactions were classified as probable. The mean time for onset of reactions was 40 minutes, being the fastest with Docetaxel (5 minutes) and the longest with Paclitaxel (180 minutes). The severity of reactions ranged from mild (64%) to moderate (30%). The most compromised organic segments were respiratory (27%) and cardiovascular (26%); and 83% of the symptoms presented were predicted in the databases. With this study, it was possible to identify the main immediate reactions to the infusion in the study group, as well as the chemotherapeutic agents involved with them, contributing to the safe management of patients and effective control of reactions by the multidisciplinary team.La mayoría de los agentes antineoplásicos pueden producir reacciones a la infusión, cuya incidencia y perfil varían según las características de cada fármaco, que pueden ser inmunomediadas o no. Con el fin de describir el perfil de reacciones adversas inmediatas a la infusión de quimioterapia en pacientes ambulatorios, se desarrolló este estudio exploratorio, descriptivo, transversal y retrospectivo, basado en registros de notificaciones de reacciones adversas realizadas por el equipo multidisciplinario de marzo / 2018 a marzo / 2019, y la historia clínica de los participantes. Las reacciones adversas inmediatas a la infusión de quimioterapia se clasificaron por gravedad de acuerdo con los Criterios de terminología común para eventos adversos y por causalidad utilizando el algoritmo de Naranjo. De un total de 6.832 instalaciones de quimioterapia intravenosa realizadas durante el período de estudio, se registraron 30 reacciones adversas inmediatas, involucrando a 28 pacientes (83% mujeres), principalmente con Paclitaxel (44%) y Carboplatino (20%). Según Naranjo, el 60% de las reacciones a la infusión se clasificaron como probables. El tiempo medio de aparición de reacciones fue de 40 minutos, siendo el más rápido con Docetaxel (5 minutos) y el más largo con Paclitaxel (180 minutos). La gravedad de las reacciones varió de leve (64%) a moderada (30%). Los segmentos orgánicos más comprometidos fueron el respiratorio (27%) y el cardiovascular (26%); y el 83% de los síntomas presentados se predijeron en las bases de datos. Con este estudio fue posible identificar las principales reacciones inmediatas a la infusión en el grupo de estudio, así como los agentes quimioterapéuticos involucrados en las mismas, contribuyendo al manejo seguro de los pacientes y al control efectivo de las reacciones por parte del equipo multidisciplinar.A maioria dos agentes antineoplásicos pode ocasionar reações infusionais, das quais a incidência e o perfil variam conforme as características de cada medicamento, podendo ou não ser imunomediadas. Com o objetivo descrever o perfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais, desenvolvemos este estudo exploratório, descritivo, transversal e retrospectivo, a partir registros das notificações das reações adversas realizados pela equipe multiprofissional de março/2018 a março/2019, e dos prontuários dos participantes. As reações adversas imediatas à infusão de quimioterapia foram classificadas quanto à gravidade, de acordo com a Common Terminology Criteria for Adverse Events, e quanto à causalidade usando algoritmo de Naranjo. De um total de 6.832 instalações endovenosas de quimioterapia realizadas no período de estudo, foram registradas 30 reações adversas imediatas, envolvendo 28 pacientes (83% mulheres), principalmente com Paclitaxel (44%) e Carboplatina (20%). Conforme Naranjo, 60% das reações infusionais foram classificadas como prováveis. O tempo médio para manifestação das reações foi de 40 minutos, sendo a mais rápida com Docetaxel (5 minutos), e a mais demorada com Paclitaxel (180 minutos). A gravidade das reações variou entre leve (64%) e moderada (30%). Os segmentos orgânicos mais comprometidos foram respiratório (27%) e cardiovascular (26%); e 83% dos sintomas apresentados estavam previstos nas bases de dados. Com este estudo, foi possível identificar as principais reações imediatas à infusão no grupo em estudo, bem como os quimioterápicos envolvidos com as mesmas, contribuindo para o manejo seguro dos pacientes e no controle eficaz das reações pela equipe multidisciplinar.Research, Society and Development2021-11-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2300910.33448/rsd-v10i15.23009Research, Society and Development; Vol. 10 No. 15; e416101523009Research, Society and Development; Vol. 10 Núm. 15; e416101523009Research, Society and Development; v. 10 n. 15; e4161015230092525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/23009/20448Copyright (c) 2021 Maihara da Silva Borges; Marcela Miranda Salles; Ranieri Carvalho Camuzihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBorges, Maihara da SilvaSalles, Marcela MirandaCamuzi, Ranieri Carvalho2021-12-06T10:13:53Zoai:ojs.pkp.sfu.ca:article/23009Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:42:00.399208Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
Perfil de reacciones adversas inmediatas a la infusión de quimioterapia en pacientes ambulatorios de un Hospital Universitario de Río de Janeiro
Perfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais em um Hospital Universitário fluminense
title Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
spellingShingle Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
Borges, Maihara da Silva
Quimioterapia
Eventos adversos
Farmacovigilância
Segurança do paciente.
Quimioterapia
Eventos adversos
Farmacovigilancia
Seguridad del paciente.
Chemotherapy
Adverse events
Pharmacovigilance
Patient safety.
title_short Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
title_full Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
title_fullStr Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
title_full_unstemmed Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
title_sort Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
author Borges, Maihara da Silva
author_facet Borges, Maihara da Silva
Salles, Marcela Miranda
Camuzi, Ranieri Carvalho
author_role author
author2 Salles, Marcela Miranda
Camuzi, Ranieri Carvalho
author2_role author
author
dc.contributor.author.fl_str_mv Borges, Maihara da Silva
Salles, Marcela Miranda
Camuzi, Ranieri Carvalho
dc.subject.por.fl_str_mv Quimioterapia
Eventos adversos
Farmacovigilância
Segurança do paciente.
Quimioterapia
Eventos adversos
Farmacovigilancia
Seguridad del paciente.
Chemotherapy
Adverse events
Pharmacovigilance
Patient safety.
topic Quimioterapia
Eventos adversos
Farmacovigilância
Segurança do paciente.
Quimioterapia
Eventos adversos
Farmacovigilancia
Seguridad del paciente.
Chemotherapy
Adverse events
Pharmacovigilance
Patient safety.
description Most antineoplastic agents can cause infusion reactions, the incidence and profile of which vary according to the characteristics of each drug, which may or may not be immune-mediated. In order to describe the profile of immediate adverse reactions to chemotherapy infusion in outpatients, we developed this exploratory, descriptive, cross-sectional and retrospective study, based on records of adverse reaction notifications carried out by the multidisciplinary team from March/2018 to March/2019, and the medical records of the participants. Adverse reactions immediate to chemotherapy infusion were ranked for severity according to the Common Terminology Criteria for Adverse Events and for causality using Naranjo's algorithm. Of a total of 6,832 intravenous chemotherapy facilities performed during the study period, 30 immediate adverse reactions were recorded, involving 28 patients (83% women), mainly with Paclitaxel (44%) and Carboplatin (20%). According to Naranjo, 60% of infusion reactions were classified as probable. The mean time for onset of reactions was 40 minutes, being the fastest with Docetaxel (5 minutes) and the longest with Paclitaxel (180 minutes). The severity of reactions ranged from mild (64%) to moderate (30%). The most compromised organic segments were respiratory (27%) and cardiovascular (26%); and 83% of the symptoms presented were predicted in the databases. With this study, it was possible to identify the main immediate reactions to the infusion in the study group, as well as the chemotherapeutic agents involved with them, contributing to the safe management of patients and effective control of reactions by the multidisciplinary team.
publishDate 2021
dc.date.none.fl_str_mv 2021-11-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/23009
10.33448/rsd-v10i15.23009
url https://rsdjournal.org/index.php/rsd/article/view/23009
identifier_str_mv 10.33448/rsd-v10i15.23009
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/23009/20448
dc.rights.driver.fl_str_mv Copyright (c) 2021 Maihara da Silva Borges; Marcela Miranda Salles; Ranieri Carvalho Camuzi
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Maihara da Silva Borges; Marcela Miranda Salles; Ranieri Carvalho Camuzi
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 15; e416101523009
Research, Society and Development; Vol. 10 Núm. 15; e416101523009
Research, Society and Development; v. 10 n. 15; e416101523009
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052790981263360